Biograph Vision.X and Biograph Vision.X Edge

The Biograph Vision.X and Biograph Vision.X Edge systems are hybrid PET/CT scanners designed for comprehensive diagnostic imaging across oncology, neurology, and cardiology by fusing anatomical CT data with metabolic PET data. Their core technological advancement lies in an updated PET detector electronics assembly that enhances Time of Flight resolution (≤ 214 ps), aiming to improve image quality and diagnostic accuracy in clinical applications.

The Biograph Vision.X and Biograph Vision.X Edge are advanced medical imaging systems that integrate X-ray Computed Tomography (CT) and Positron Emission Tomography (PET) capabilities. These systems are designed to provide healthcare professionals with fused high-resolution anatomical and physiological information, aiding in the detection, localization, diagnosis, staging, and restaging of various conditions including cancer, cardiovascular disease, and neurological disorders. The CT component generates detailed cross-sectional anatomical images using X-ray transmission data, while the PET subsystem images the distribution of radiopharmaceuticals to reveal metabolic and physiologic functions. The system allows for independent CT or PET imaging and supports applications like radiotherapy treatment planning, interventional radiology guidance, and low-dose CT lung cancer screening for high-risk individuals. A significant enhancement in the Biograph Vision.X and Vision.X Edge models is an updated PET detector electronics assembly (DEA), specifically engineered to improve Time of Flight (ToF) resolution, a critical factor for image quality in PET. The accompanying software, while maintaining the core functionalities of patient management, data handling, image reconstruction, and DICOM-compliant image evaluation from previous versions, has been modified to support these new hardware configurations and incorporates cybersecurity measures. Performance testing, referenced against the NEMA NU2-2018 standard using data from the Biograph Vision Quadra system, demonstrated that the system met all acceptance criteria for key PET metrics, including spatial resolution, sensitivity, count rate performance, scatter fraction, co-registration accuracy, and an improved Time of Flight resolution of ≤ 214 ps, indicating its capability for high-quality diagnostic imaging.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the improved Time of Flight resolution (≤ 214 ps) in the Biograph Vision.X/Edge translate to quantifiable improvements in lesion detectability or diagnostic confidence compared to its predicate device (Biograph Vision 600/Edge)?; What specific modifications were made to the PET detector electronics assembly (DEA) to achieve the enhanced Time of Flight resolution, and are there any associated trade-offs (e.g., in sensitivity or other performance parameters)?; The NEMA performance data provided is for the Biograph Vision Quadra system; how directly do these specific performance values (e.g., resolution, sensitivity, NECR) apply to the Biograph Vision.X and Vision.X Edge models, and are there any differences in detector configuration or axial field of view?; What are the practical implications of the updated software and cybersecurity controls for clinical workflow integration and data management, particularly concerning interoperability with existing hospital PACS and RIS systems?; For low-dose CT lung cancer screening, what are the specific dose levels achievable with the Biograph Vision.X/Edge, and how do these compare to established guidelines and other dedicated CT screening systems?